Catheter Precision Inc. (AMEX:VTAK) does about 3.38M shares in volume on a normal day but saw 1634445 shares change hands in the recent trading day. The company now has a market cap of 1.74M USD. Its current market price is $0.62, marking a decrease of -29.17% compared to the previous close of $0.88. The 52 week high reached by this stock is $8.40 whilst the lowest price level in 52 weeks is $0.31.
Catheter Precision Inc. (VTAK) has a 20-day trading average at $0.5092 and the current price is -92.62% off the 52-week high compared with 99.26% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.7481 and its 200-day simple moving average is $3.5650. If we look at the stock’s price movements over the week, volatility stands at 19.44%, which decreases to 18.42% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.31 to suggest the stock is neutral.
The consensus objective for the share price is $41.00, suggesting that the stock has a potential upside of 98.49% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 13, 2019 when Piper Jaffray downgraded the stock to “Neutral” and issued a price target of between $9 and $1.50.
The current price level is 21.77%, -17.11%, and -82.61% away from its SMA20, SMA50, and SMA200 respectively, with the VTAK price moving above the 50-day SMA on current market day. Catheter Precision Inc. (VTAK) stock is down -31.86% over the week and 45.67% over the past month. Its price is -84.66% year-to-date and -83.77% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -11.5 below consensus estimates by -8.48. The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $1.66M, which analysts say will come at $3.19M for the current fiscal year and next year at $8.85M. In addition, estimates put the company’s current quarterly revenue at an average of $1.06M.
To reach the target analysts have set, the stock logically needs to grow 98.49 percent from here.
Outstanding shares total 2.80M with insiders holding 16.78% of the shares and institutional holders owning 2.53% of the company’s common stock. The company has a return on investment of -41.37% and return on equity of -49.81%. The beta has a value of -0.41. Price to book ratio is 0.03 and price to sales ratio is 3.95.
